Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Dupixent prep > Selling Messages > Flashcards

Selling Messages Flashcards

1
Q

Control more than one measure of uncontrolled asthma…
(3 measures)

A

Exacerbation reduction - up to 81% significant reduction in annualized rate of severe exacerbation thru week 24

Lung function improvement- rapid FEV (forced expiratory volume) at week 2 and sustained thru week 52

OCS reduction / elimination - 86% of patients reduced or eliminated their OCS at week 24

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Treat more than one asthma patient type… specifically indicated for ______ Dependent _______ Patients and for moderate to ________ Asthma patients with ___________ phenotype

A

OCS
ASTHMA
SEVERE
EOSINOPHILLIC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Targets more than one ___ of type __________ By specifically __________ IL_ and IL_ ___________

A

Source
Type 2 inflammation
Inhibiting IL4 and IL13
Signalling

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Markers of type 2 inflammation
(Proven data in indicated patients with >1 of the following)

A

EOS > 150 cells / microliter
igE > 30 IU / mL
FeNO > 20 ppb
(Fractional exhaled nitric oxide - measures airway inflammation)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Prescribed to ______ patients since ________ in patients aged ____ with moderate to severe asthma

A

116k
2018
12+

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

MOA
Only Dupixent targets both ____ and ____ ___________, two of the key ________ Of local and ______ type __ ___________

A

IL4 and IL13
Signalling
Drivers
Systemic
Type 2 inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Patients on medium to high OCS dose + one or more controller
% and mL improvement

A

~72% of the total improvement at week 2…. 470mL improvement at week 52 (placebo 170mL)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

The higher the EOS, the better the improvement (QUEST) — lung function improvement in patients with elevated EOS

A

EOS > 150 cells - 390ml improvement (150mL diff)
EOS > 300 - 480ml (250 diff)
EOS > 500 - 570ml (300 diff)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Patients on medium to high ICS dose + one or more controller
QUEST primary end point
Up to ____ % reduction in _________ through week _______

A

81%
Severe exacerbations thru week 24

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Patients on medium to high ICS dose + one or more controller
QUEST primary end point
____ % of patients did not have an _______ requiring ________ or ED visit thru weeks ___ to ___.

A

97%
Exacerbation
Hospitalization
48 to 96 weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Patients on medium ICS dose + one or more controller
QUEST primary end point
Severe exacerbations thru W52
____ % reduction in severe exacerbations thru week 52
___ severe exacerbations thru week 96

A

71%
Zero

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Patients on medium ICS dose + one or more controller
Rapid lung function improvement patients can feel as early as week 2
__% of the total improvement at week __
___ mL improvement at week ____
Up to ___ years of _____ relief

A

75%
510mL
3 years of breathing relief

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Side effects of maintenance OCS
Short term - SPF
Long term - OCD

A

Short term
Sleep disturbance
Increases risk of fracture
Pneumonia

Long term
Obesity
Diabetes
Cataracts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Dupixent is the only FDA-approved biological indicated for ___________ patients.

A

OCS-dependent asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

79% of patients from _______ eliminated their OCS dose for up to E years

A

VENTURE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Dupixent improved asthma control in patients 12+ years as measured by ACQ-5
Up to __% Improved asthma ______
With Dupixent ___mg Q2W + SOC vs ___% With placebo + SOC

A

75%
Asthma control
200
67%

17
Q

Dupixent improved QOL for 12+
__% vs __%

A

71% vs 55%

18
Q

Most common side effects…

A

Injection site reactions
Oropharyngeal pain (pharynx)
Eosinophilia (high)

19
Q

Dupixent is a _____-recognized treatment option for children with asthma aged __ to ___ and has a demonstrated ____ profile

A

GINA - Global initiative for asthma
6-11
Safety

20
Q

Dupixent significantly reduce severe exacerbations in children, age 6 to 11 years old
Annualized rate of severe exacerbations thru week 52 in eosinophilic phenotype (VOYAGE, primary endpoint)
EOS > 150 cells or FENO > 20ppb = ___ % reduction
EOS > 300 = ___ % reduction

A

59% reduction
65% reduction

21
Q

Dupixent sustained lung function, improvement in children, aged 6 to 11 years
_x improvement was seen with D at W12 in percent predicted pre-bronchialator FEV vs placebo
_x improvement at week 52

A

2x
3x

22
Q

Dupixent reduced SCS use and improved asthma, control in children, aged 6 to 11 years
SCS reduction thru week 52
___% for EOS150, Feno20
___% for EOS300

A

59%
66%

23
Q

Long term SCS use may have significant side effects in children
LIGB

A

Lower height in adulthood
Increased susceptibility to infection
Gastrointestinal and cardiovascular complications
Behavioral changes

24
Q

SCS

A

Systemic corticosteroids
Prednisone

25
Q

Dosage for adults and peds 12+

A

600mg load + 300mg Q2W (2mL solution)
OR
400mg load + 200mg Q2W (1.14mL solution)

26
Q

Dosage for children (6-11 years)

A

No loading dose
15-30kg - 300mg every four weeks
30+ kg - 200mg every two weeks

27
Q

1 biologic prescribed by ______

# 1 biologic prescribed by ______ for ____ patients

A

Allergists
Pulmonologists for asthma

28
Q

Dupixent studied in ___ clinical trials with more than _____ patients 12+.
Approved on _____ 19, _____

A

3
2,800
October 2018

29
Q

Dupixent studied in ___ clinical trials with more than _____ patients 6-11 years.
Approved on _____ 20, _____

A

1
400
October 2021

30
Q

Competitors

A

Fasenra (benralizumab) GSK
Nucala (mepolizumab) AZ

31
Q

Uncontrolled Asthma is defined as uncontrolled when a patient experiences ___ to ____ of the following symptoms in a __ week span:
- interrupted _______
- _____ asthma symptoms more than ___ a week
- ______ _________ use more than _____ a week
- missed or ________ activities due to asthma

A

3-4
4 week span

interrupted sleep
daytime asthma more than 2x a week
rescue inhaler use more than 2x a week
missed or limited activities due to asthma

32
Q

OCS Dependent Asthma
OCS dependent asthma is asthma that is either uncontrolled or _____ to _______ that relies on OCS in addition to other medications to:
- help treat or maintain ____ symptom _______
- reduce the risk of __________

A

difficult to treat

good symptom control
reduce the risk of attacks

33
Q
A

Dupixent prep (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions